NASDAQ:TBPH Theravance Biopharma Q2 2026 Earnings Report $17.02 -0.02 (-0.12%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$17.02 +0.00 (+0.03%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Theravance Biopharma EPS ResultsActual EPS-$0.11Consensus EPS $0.07Beat/MissMissed by -$0.18One Year Ago EPSN/ATheravance Biopharma Revenue ResultsActual Revenue$20.73 millionExpected Revenue$22.49 millionBeat/MissMissed by -$1.76 millionYoY Revenue GrowthN/ATheravance Biopharma Announcement DetailsQuarterQ2 2026Date8/10/2026TimeBefore Market OpensConference Call DateMonday, August 10, 2026Conference Call Time8:30AM ETUpcoming EarningsTheravance Biopharma's Q3 2026 earnings is estimated for Tuesday, November 10, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Theravance Biopharma Earnings HeadlinesZymeworks' Theravance Deal Is A Breath Of Fresh Cash FlowSeptember 18 at 3:42 PM | seekingalpha.comTheravance Biopharma IncAugust 20, 2026 | money.usnews.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.September 19 at 1:00 AM | Weiss Ratings (Ad)TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its ShareholdersAugust 15, 2026 | businesswire.comTheravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 10, 2026 | prnewswire.comZymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial ResultsAugust 6, 2026 | financialpost.comFSee More Theravance Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Theravance Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Theravance Biopharma and other key companies, straight to your email. Email Address About Theravance BiopharmaTheravance Biopharma (NASDAQ:TBPH) is a biopharmaceutical company focused on developing and commercializing medicines for serious respiratory and immune-mediated diseases. The company’s work centers on therapies designed to address significant unmet medical needs and improve treatment options for patients. Its principal commercial product is YUPELRI (revefenacin), a once-daily nebulized long-acting muscarinic antagonist used as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults. YUPELRI is commercialized in the United States through a collaboration with Viatris. Theravance Biopharma also maintains research and development programs focused on respiratory and immunology applications. The company was established in 2013 following the separation of the biopharmaceutical operations of Theravance, Inc. It is headquartered in Dublin, Ireland, with additional operations in the United States. Theravance Biopharma is led by Rick E. Winningham, who serves as chief executive officer and chairman.View Theravance Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the LimitsCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
